Table 2 Anemia and the risk of cardiovascular events or all-cause mortality.

From: Impact of anemia requiring transfusion or erythropoiesis-stimulating agents on new-onset cardiovascular events and mortality after continuous renal replacement therapy

 

Control

(N = 2428)

Anemia

(N = 8495)

Crude

HR (95% CI)

Adjusted*

HR (95% CI)

No. of events (% per patient-year)

Cardiovascular events†

141 (1.6)

481 (2.0)

1.17 (0.98–1.41)

1.05 (0.85–1.29)

Heart failure

35 (0.4)

109 (0.4)

1.24 (0.89–1.71)

1.08 (0.72–1.62)

Acute myocardial infarction

14 (0.2)

59 (0.2)

1.47 (0.86–2.49)

1.50 (0.86–2.62)

Revascularization

25 (0.3)

83 (0.3)

1.18 (0.78–1.77)

1.36 (0.89–2.08)

Stroke

87 (1.0)

285 (1.2)

1.12 (0.88–1.43)

0.97 (0.75–1.27)

All-cause mortality

771 (8.4)

4,323 (17.3)

1.87 (1.73–2.02)

1.41 (1.30–1.53)

  1. *Adjusted for age, sex, tertiary hospital, comorbidities, septic shock, CRRT duration, and mechanical ventilation.
  2. †A composite outcome of heart failure, acute myocardial infarction, revascularization, or stroke.
  3. CI confidence interval, HR hazard ratio.
Back to article page